Sugi Predict

Sugi Predict / Compounds / SCHEMBL519364

SCHEMBL519364

SCHEMBL519364

CCS(=O)(=O)Nc1cccc(B(O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 1/20 0.45
▸ AURKA O14965 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ HPGD P15428 4/20 0.44
▸ LMNA P02545 2/20 0.44
▸ BRD4 O60885 3/20 0.44
▸ ADRA2A P08913 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ BRDT Q58F21 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ LPL P06858 1/20 0.41
▸ LIPG Q9Y5X9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519912 0.89 AURKA (0.48) NLRP3AURKAKDRAURKBBRD4
SCHEMBL29954021 0.86 AURKA (0.50) NLRP3AURKAKDRAURKBHPGD
SCHEMBL173028 0.83 ALDH1A1 (0.56) NLRP3AURKAKDRAURKBHPGD
SCHEMBL19893801 0.83 TRPV1 (0.39) NLRP3AURKAKDRAURKB
SCHEMBL693060 0.80 ADRB3 (0.39) NLRP3AURKAKDRAURKBBRD4
SCHEMBL23191109 0.79 ENPP2 (0.42) NLRP3HTT
SCHEMBL12077561 0.79 HPGD (0.58) AURKAKDRAURKBHPGDLMNA
SCHEMBL6666 0.79 HTT (0.59) NLRP3HPGDBRD4HTTSMN1; SMN2
SCHEMBL29955257 0.79 HTT (0.59) NLRP3HPGDBRD4HTTSMN1; SMN2
SCHEMBL15330286 0.79 KDM1A (0.45) NLRP3LMNABRD4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
CN-112094266-B Pyrrolopyridinone compound, preparation method, composition and application thereof 中国科学院上海药物研究所 2023-03-21 — — CN disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
EP-3640241-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-09-28 — — EP disclosed
CN-108558889-B Bromodomain inhibitors 赛尔基因昆蒂赛尔研究公司 2021-11-05 — — CN disclosed
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 — — EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 — — US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 — — US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 — — EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 — — WO disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 — — US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 — — US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 — — US disclosed
EP-1519915-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-04-06 — — EP disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 NLRP3 3492/4885AURKA 860/4885KDR 4386/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 NLRP3 3492/4885AURKA 860/4885KDR 4386/4885
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 NLRP3 3203/4885AURKA 4346/4885KDR 3624/4885
US-10941160-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 NLRP3 3492/4885AURKA 860/4885KDR 4386/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 NLRP3 3492/4885AURKA 860/4885KDR 4386/4885
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 NLRP3 2414/4885AURKA 451/4885KDR 527/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 NLRP3 3171/4885AURKA 4259/4885KDR 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.